In the Phase 2a part of the GOAL-HF1 study, a total of 26 patients were randomized to receive AC01 or placebo for 28 days at dose levels identified from the previously completed Phase 1b part, which dosed patients over 7 days.

The study has been designed in collaboration with a panel of senior heart failure experts and is being conducted at 13 highly specialized heart failure centers in Sweden, the Netherlands, Italy and the UK, describes the company.

Related article

Global health & Local efforts: Strengthening the heart

Cardiovascular diseases have a high mortality rate and although prevention is key, there are many companies, including Nordic ones, determined to develop better treatments.

“Completing the target enrollment on schedule in the Phase 2a study part is an important achievement for AnaCardio and demonstrates great execution by our team and partners,” says Elin Rosendahl, Chief Development Officer at AnaCardio.

“We are excited to advance AC01 through this critical stage of development, with data expected later this year. With AC01’s novel mechanism and encouraging clinical profile to date, we believe it has the potential to transform the treatment paradigm in patients with HFrEF.”